Table of Content

1. PREFACE
1.1. Introduction
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Considerations
2.6.1. Demographics
2.6.2. Economic Factors
2.6.3. Government Regulations
2.6.4. Supply Chain
2.6.5. COVID Impact / Related Factors
2.6.6. Market Access
2.6.7. Healthcare Policies
2.6.8. Industry Consolidation
2.7. Key Market Segmentation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Structure of Antibodies
5.3. History of Antibody Development
5.4. Antibody Isotypes
5.5. Mechanism of Action of Antibodies
5.6. Classification of Antibodies
5.6.1. Monoclonal Antibodies
5.6.2. Polyclonal Antibodies
5.6.3. Bispecific Antibodies
5.7. Applications of Antibodies
5.8. Concluding Remarks

6. ANTIBODY DISCOVERY: PROCESS AND METHODS
6.1. Chapter Overview
6.2. Antibody Discovery Process
6.2.1. Target Selection and Validation
6.2.2. Hit Generation
6.2.3. Lead Selection
6.2.4. Lead Optimization
6.2.4.1. Humanization
6.2.4.2. Affinity Maturation
6.2.4.3. Fc Engineering
6.2.5. Lead Characterization
6.2.6. Candidate Selection
6.3. Antibody Discovery Methods
6.3.1. Hybridoma Technology-based Method
6.3.2. In vitro Display Method
6.3.2.1. Phage Display
6.3.2.2. Yeast Display
6.3.2.3. Ribosomal Display
6.3.3. Transgenic Animal-based Method
6.3.4. Single B Cell-based Method
6.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques
6.4. Evolution of Monoclonal Antibodies
6.4.1. Fully Human Monoclonal Antibodies
6.5. Concluding Remarks

7. ANTIBODY DISCOVERY SERVICE PROVIDERS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers: List of Industry Players
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Type of Antibody Discovery Services Offered
7.2.5. Analysis by Type of Antibody Discovered
7.2.6. Analysis by Type of Antibody Discovery Method
7.2.7. Analysis by Animal Model Used
7.2.8. Analysis by Type of Antibody Discovered and Type of Antibody Discovery Method
7.2.9. Analysis by Type of Antibody Discovery Services and Location of Headquarters
7.2.10. Analysis by Application Area

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Companies Grouped Grouped based on Company Size
8.4.1. Very Small Companies Offering Antibody Discovery Services
8.4.2. Small Companies Offering Antibody Discovery Services
8.4.3. Mid-sized Companies Offering Antibody Discovery Services
8.4.4. Large Companies Offering Antibody Discovery Services
8.5. Antibody Discovery Service Providers: Regional Capability
8.5.1. Antibody Discovery Service Providers based in North America
8.5.2. Antibody Discovery Service Providers based in Europe
8.5.3. Antibody Discovery Service Providers based in Asia

9. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
9.1. Chapter Overview
9.2. Antibody Discovery Service Providers in North America
9.2.1. Abwiz Bio
9.2.1.1. Company Overview
9.2.1.2. Recent Developments and Future Outlook
9.2.2. Abzena
9.2.2.1. Company Overview
9.2.2.2. Recent Developments and Future Outlook
9.2.3. Aragen Life Sciences
9.2.3.1. Company Overview
9.2.3.2. Recent Developments and Future Outlook
9.2.4. Capralogics
9.2.4.1. Company Overview
9.2.4.2. Recent Developments and Future Outlook
9.2.5. Creative Biolabs
9.2.5.1. Company Overview
9.2.5.2. Financial Information
9.2.5.3. Recent Developments and Future Outlook
9.2.6. DetaiBio
9.2.6.1. Company Overview
9.2.6.2. Recent Developments and Future Outlook
9.2.7. ImmunoPrecise Antibodies
9.2.7.1. Company Overview
9.2.7.2. Financial Information
9.2.7.3. Recent Developments and Future Outlook
9.2.8. Integral Molecular
9.2.8.1. Company Overview
9.2.8.2. Recent Developments and Future Outlook
9.2.9. Syd Labs
9.2.9.1. Company Overview
9.2.9.2. Recent Developments and Future Outlook
9.3. Antibody Discovery Service Providers in Europe
9.3.1. BIOTEM
9.3.1.1. Company Overview
9.3.1.2. Recent Developments and Future Outlook
9.3.2. FairJourney Biologics
9.3.2.1. Company Overview
9.3.2.2. Recent Developments and Future Outlook
9.3.3. Fusion Antibodies
9.3.3.1. Company Overview
9.3.3.2. Recent Developments and Future Outlook
9.3.4. Proteogenix
9.3.4.1. Company Overview
9.3.4.2. Recent Developments and Future Outlook
9.3.5. RD Biotech
9.3.5.1. Company Overview
9.3.5.2. Recent Developments and Future Outlook
9.4. Antibody Discovery Service Providers in Asia
9.4.1. ABGENEX
9.4.1.1. Company Overview
9.4.1.2. Recent Developments and Future Outlook
9.4.2. ChemPartner
9.4.2.1. Company Overview
9.4.2.2. Recent Developments and Future Outlook
9.4.3. Viva Biotech
9.4.3.1. Company Overview
9.4.3.2. Financial Information
9.4.3.3. Recent Developments and Future Outlook
9.4.4. WuXi Biologics
9.4.4.1. Company Overview
9.4.4.2. Financial Information
9.4.4.3. Recent Developments and Future Outlook

10. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET LANDSCAPE
10.1. Chapter Overview
10.2. Antibody Discovery: List of Technologies
10.2.1. Analysis by Type of Antibody Discovery Method
10.2.2. Analysis by Type of Antibody Discovered
10.2.3. Analysis by Animal Model Used
10.2.4. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
10.2.5. Analysis by Type of Antibody Discovery Method and Location of Headquarters
10.3. Antibody Discovery Technologies: Developer Landscape
10.3.1. Analysis by Year of Establishment
10.3.2. Analysis by Company Size
10.3.3. Analysis by Location of Headquarters
10.3.4. Most Active Players: Analysis by Number of Technologies
11. TECHNOLOGY COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Antibody Discovery Technologies: Competitiveness Analysis
11.4.1. Antibody Discovery Technologies Offered by Companies based in North America
11.4.2. Antibody Discovery Technologies Offered by Companies based in Europe
11.4.3. Antibody Discovery Technologies Offered by Companies based in Asia and Rest of the World
12. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
12.1. Chapter Overview
12.2. Ablexis
12.2.1. Company Overview
12.2.2. Antibody Discovery Platform Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. Creative Biolabs
12.3.1. Company Overview
12.3.2. Antibody Discovery Platform Portfolio
12.3.3. Recent Developments and Future Outlook
12.4. Genmab
12.4.1. Company Overview
12.4.2. Financial Information
12.4.3. Antibody Discovery Platform Portfolio
12.4.4. Recent Developments and Future Outlook
12.5. Harbour Biomed
12.5.1. Company Overview
12.5.2. Financial Information
12.5.3. Antibody Discovery Platform Portfolio
12.5.4. Recent Developments and Future Outlook
12.6. Immunome
12.6.1. Company Overview
12.6.2. Antibody Discovery Platform Portfolio
12.6.3. Recent Developments and Future Outlook
12.7. Isogenica
12.7.1. Company Overview
12.7.2. Antibody Discovery Platform Portfolio
12.7.3. Recent Developments and Future Outlook
12.8. Ligand Pharmaceuticals
12.8.1. Company Overview
12.8.2. Financial Information
12.8.3. Antibody Discovery Platform Portfolio
12.8.4. Recent Developments and Future Outlook
12.9. Kymab
12.9.1. Company Overview
12.9.2. Antibody Discovery Platform Portfolio
12.9.3. Recent Developments and Future Outlook
12.10. MorphoSys
12.10.1. Company Overview
12.10.2. Financial Information
12.10.3. Antibody Discovery Platform Portfolio
12.10.4. Recent Developments and Future Outlook

13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. List of Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year of Partnership and Type of Partner
13.3.4. Analysis by Type of Antibody
13.3.5. Most Active Players: Analysis by Number of Partnerships
13.3.6. Most Popular Technologies: Analysis by Number of Partnerships
13.3.7. Analysis by Geography
13.3.8. Intracontinental and Intercontinental Agreements

14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. Antibody Discovery Service and Platform Providers: Funding and Investment
14.3.1. Analysis by Year of Funding
14.3.2. Analysis by Type of Funding
14.3.3. Analysis of Amount Invested by Year of Funding
14.3.4. Analysis by Year-wise Number of Funding Instances and Funding Amount
14.3.5. Most Active Players: Analysis by Number of Funding Instances
14.3.6. Most Active Players: Analysis by Amount Invested
14.3.7. Leading Investors: Analysis by Number of Funding Instances
14.3.8. Analysis by Year-wise Number of Funding Instances and Type of Player
14.3.9. Analysis by Year-wise Amount Invested and Type of Player
14.3.10. Analysis of Number of Funding Instances by Year of Establishment and Type of Player
14.3.11. Analysis by Geography
14.4. Concluding Remarks

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion

16. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
16.3.1. Scenario Analysis
16.4. Key Market Segmentations
16..5. Dynamic Dashboard

17. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF SERVICE OFFERED
17.1. Chapter Overview
17.2. Key Assumptions and Methodology

17.3. Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.4. Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.5. Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.6. Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.7. Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.8. Data Triangulation and Validation

18. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.4. Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.5. Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.6. Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.7. Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.8. Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.9. Data Triangulation and Validation

19. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY DISCOVERED
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Humanized: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.4. Human: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.5. Chimeric: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.6. Murine: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.7. Data Triangulation and Validation

20. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF THERAPEUTIC AREAS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.4. Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.5. Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.6. Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.7. Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.8. Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.9. Data Triangulation and Validation
21. ANTIBODY DISCOVERY SERVICES MARKET, BY KEY GEOGRAPHIES
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.6. Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.7. Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.8. Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.9. Data Triangulation and Validation
22. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES MARKET
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
22.3.1. Scenario Analysis
22.4. Key Market Segmentations
22.5. Dynamic Dashboard
23. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY TYPE OF ANTIBODY DISCOVERED
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.4. Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.5. Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.6. Data Triangulation and Validation
24. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY KEY GEOGRAPHIES
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.6. Data Triangulation and Validation
25. LICENSING DEAL STRUCTURE
25.1. Chapter Overview
25.2. Key Parameters
25.3. Assumptions and Methodology
25.3.1. Overall Cash Flow for Licensee Companies
25.3.1.1. Investments Made by a Licensee
25.3.1.2. Revenues Earned by a Licensee

25.3.2. Overall Cash Flow for Licensor Companies
25.3.2.1. Investments Made by a Licensor
25.3.2.2. Revenues Earned by a Licensor
25.4. Key Analytical Outputs
25.4.1. Scenario 1: Variation of Upfront and Milestone Payments
25.4.2. Scenario 2: Variation of Upfront Payments and Sales-based Royalties
25.4.3. Scenario 3: Variation of Milestone Payments and Sales-based Royalties
26. SWOT ANALYSIS: ANTIBODY HUMANIZATION SERVICE PROVIDERS
26.1. Chapter Overview
26.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: List of Players
26.3. Antibody Humanization Service Providers: SWOT Analysis
26.3.1. Strengths
26.3.2. Weaknesses
26.3.3. Opportunities
26.3.4. Threats
27. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
27.1. Chapter Overview
27.2. Humira? (Adalimumab)
27.2.1. Drug Overview
27.2.2. Discovery Process and Method
27.2.3. Historical Sales
27.3. Keytruda? (Pembrolizumab)
27.3.1. Drug Overview
27.3.2. Discovery Process and Method
27.3.3. Historical Sales
27.4. Stelara? (Ustekinumab)
27.4.1. Drug Overview
27.4.2. Discovery Process and Method
27.4.3. Historical Sales
27.5. Dupixent? (Dupilumab)
27.5.1. Drug Overview
27.5.2. Discovery Process and Method
27.5.3. Historical Sales
27.6. Opdivo? (Nivolumab)
27.6.1. Drug Overview
27.6.2. Discovery Process and Method
27.6.3. Historical Sales
28. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
28.1. Chapter Overview
28.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
28.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
28.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
28.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
28.6. Future Growth Opportunities in the Asia and Rest of the World
28.7. Expected Increase in Number of Collaborations and Licensing Activity
28.8 Concluding Remarks
29. CONCLUSION

30. EXECUTIVE INSIGHTS

30.1. Chapter Overview

30.2. Antibody Solutions

30.2.1. Company Snapshot

30.2.2. Interview Transcript

30.3. Adimab

30.3.1. Company Snapshot

30.3.3. Interview Transcript

30.4. ImmunoPrecise Antibodies

30.4.1. Company Snapshot

30.4.3. Interview Transcript

30.5. Anonymous

30.5.1. Anonymous, Chief Business Officer (Q3 2023)

30.6. Abveris, Acquired by Twist Biosciences

30.6.1. Company Snapshot

30.6.2. Interview Transcript

30.7. Nidus BioSciences

30.7.1. Company Snapshot

30.7.2. Interview Transcript

30.8. AvantGen

30.8.1. Company Snapshot

30.8.2. Interview Transcript

30.9. Single Cell Technology

30.9.1. Company Snapshot

30.9.2. Interview Transcript

30.10. Distributed Bio

30.10.1. Company Snapshot

30.10.2. Interview Transcript

30.11. AbCellera

30.11.1. Company Snapshot

30.11.2. Interview Transcript

30.12. AbGenics Life Sciences

30.12.1. Company Snapshot

30.12.2. Interview Transcript

30.13. CDI Laboratories

30.13.1. Company Snapshot

30.13.2. Interview Transcript

30.14. AP Biosciences

30.14.1. Company Snapshot

30.14.2. Interview Transcript

30.15. YUMAB

30.15.1. Company Snapshot

30.15.2. Interview Transcript

30.16. Antibody Solutions

30.16.1. Company Snapshot

30.16.2. Interview Transcript

30.17. Ligand Pharmaceuticals

30.17.1. Company Snapshot

30.17.2. Interview Transcript

30.18. LakePharma

30.18.1. Company Snapshot

30.18.2. Interview Transcript

31. APPENDIX 1: TABULATED DATA

32. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION